Muzaffar Qazilbash

Plasma cell leukemia… OBSCENE 👿 #hemepath For the new #pathology resident and learners: the Dutcher bodies (nuclear Ig inclusions in the pink circle) are a very helpful clue.

Just published in @CancerMedicine 15 years of PBSC mobilization experience in Myeloma Even in the CAR-T era, collecting sufficient PBSCs is crucial. - GCSF+plerixafor comparable to chemo mobilization - If prior RT (to hematopoietic sites - spine, pelvis), chemo-mobn is better

Dr. Hagop Kantarjian, the renowned cancer researcher and clinician, is stepping down as chair of MD Anderson's leukemia department after more than 30 years. New from @HoustonChron houstonchronicle.com/health/article…

Will AI make you stupid? (from @TheEconomist) economist.com/science-and-te…

Scientific jargon can be ‘satisfying’ — but misleading nature.com/articles/d4158…

Visualizing amyloidosis: The role of radionuclide imaging in systemic amyloidosis #mmsm #bmtsm #amyloidosis @BloodPortfolio ashpublications.org/blood/article-…

Bela-Vd vs. Dara-Vd in RRMM (DREAMM-7 trial): updated OS analysis after 39-month median FU. Significant OS, PFS, MRD -ve, and DOR benefits with Bela-Vd @mmsm @dra_v_hungria @mvmateos @TheLancetOncol thelancet.com/journals/lanon…

Patient-reported outcomes with Bela-Vd vs. Dara-Vd in RRMM (DREAMM-7 trial). Most patients in both arms reported being “not at all,” “a little,” or “somewhat” bothered by treatment side-effects #mmsm @dra_v_hungria @mvmateos @TheLancetHaem thelancet.com/journals/lanha…

Negative trial for Anselamimab in AL amyloidosis #mmsm ➡️ astrazeneca.com/media-centre/p… ✅Daratumumab was permitted (not required) as part of ttt regimen,~ 80% of patients got daratumumab as part of their ttt 🛑press release with improvement in certain subgroups (not defined)…

Check our recent work @BloodAdvances @UAMSMyeloma led by @asis_shr #mmsm The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia ➡️n=16 sPCL, ORR: 31% (lower than typical MM ORR ~63%) ➡️Prior BCMA exposure = no response - all 4 patients with…

The world is making impressive progress averting cancer economist.com/briefing/2025/…

#Myeloma Paper of the Day: Case series of teclistamab in myeloma patients w/ secondary plasma cell leukemia (#PCL) shows median PFS of only 27 days (responders had PFS of 4.6 months) and none of those with prior BCMA therapy exposure had a response: pubmed.ncbi.nlm.nih.gov/40674710/. #mmsm

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development #mmsm #bmtsm @SagarLonialMD @BloodCancerJnl nature.com/articles/s4140…

@US_FDA ODAC- Blenrep ➡️The major issue is that if someone will use Blenrep, will not be using it with the combination regimen studied as well as per the dosing used (so ODAC voting was justified IMO)- if low dose/frequency is the way to use then study it in a prospective…

Real-world data provide a CARbon copy for ide-cel #mmsm #bmtsm @TMSchmidtMD @BloodPortfolio ashpublications.org/blood/article/…

SOC Ide-cel for RRMM: A CIBMTR Analysis. N=821, median prior LOT: 7, 15% with prior anti-BCMA Rx. ORR/CR: 73/25%, median PFS: 8.8 months. NRM: 6%, SPM: 4%. #mmsm #bmtsm @SurbhiSidanaMD @NausheenAhmedMD @bmtdoc63 @CIBMTR ashpublications.org/blood/article/…

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations #leusm #bmtsm @BloodPortfolio ashpublications.org/blood/article/…

Richter transformation recommendations #leusm #bmtsm @BloodPortfolio ashpublications.org/blood/article/…

Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis nature.com/articles/s4137…

Solitary but not simple─SPMs demonstrate marked heterogeneity in outcomes. The emergence of molecular and cytogenetic data to guide personalised management is the foundational step to improving outcomes. ⁦@MayoMyeloma⁩ ⁦@VincentRK⁩ nature.com/articles/s4137…